Literature DB >> 21924377

Antimalarial activity of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) and its carboxylic acid derivatives.

Akira Sato1, Satoru Kawai, Akiko Hiramoto, Masayuki Morita, Natsuki Tanigawa, Yukari Nakase, Yuka Komichi, Masahiro Matsumoto, Osamu Hiraoka, Kazuyuki Hiramoto, Hidekazu Tokuhara, Araki Masuyama, Masatomo Nojima, Kazutaka Higaki, Hikoya Hayatsu, Yusuke Wataya, Hye-Sook Kim.   

Abstract

Malaria is one of the world's deadliest diseases and is becoming an increasingly serious problem as malaria parasites develop resistance to most of the antimalarial drugs used today. We previously reported the in vitro and in vivo antimalarial potencies of 1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) and 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against Plasmodium falciparum and Plasmodium berghei parasites. To improve water-solubility for synthetic peroxides, a variety of cyclic peroxides having carboxyl functionality was prepared based on the antimalarial candidate, N-251, and their antimalarial activities were determined. The reactions of N-89 and its derivatives with Fe(II) demonstrated a highly efficient formation of the corresponding carbon radical which may be suspected as a key for the antiparasitic activity. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21924377     DOI: 10.1016/j.parint.2011.08.017

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  4 in total

1.  Improvement of Oral Bioavailability of N-251, a Novel Antimalarial Drug, by Increasing Lymphatic Transport with Long-Chain Fatty Acid-Based Self-Nanoemulsifying Drug Delivery System.

Authors:  Chikako Imada; Takuma Takahashi; Makoto Kuramoto; Kazufumi Masuda; Ken-Ichi Ogawara; Akira Sato; Yusuke Wataya; Hye-Sook Kim; Kazutaka Higaki
Journal:  Pharm Res       Date:  2015-02-27       Impact factor: 4.200

2.  Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.

Authors:  Weilin Gu; Youki Ueda; Hiromichi Dansako; Shinya Satoh; Nobuyuki Kato
Journal:  FASEB Bioadv       Date:  2021-03-04

3.  New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Authors:  Youki Ueda; Midori Takeda; Kyoko Mori; Hiromichi Dansako; Takaji Wakita; Hye-Sook Kim; Akira Sato; Yusuke Wataya; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

4.  Multiple antiviral activities of the antimalarial and anti-hepatitis C drug candidates N-89 and N-251.

Authors:  Youki Ueda; Weilin Gu; Hiromichi Dansako; Hye-Sook Kim; Sayaka Yoshizaki; Nobuaki Okumura; Tomohiro Ishikawa; Hironori Nishitsuji; Fumihiro Kato; Takayuki Hishiki; Shinya Satoh; Koji Ishii; Michiaki Masuda; Kunitada Shimotohno; Masanori Ikeda; Nobuyuki Kato
Journal:  Biochem Biophys Rep       Date:  2018-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.